Compare FICO & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | INSM |
|---|---|---|
| Founded | 1956 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3B | 22.4B |
| IPO Year | 1995 | 2000 |
| Metric | FICO | INSM |
|---|---|---|
| Price | $954.16 | $120.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 24 |
| Target Price | ★ $1,689.92 | $201.17 |
| AVG Volume (30 Days) | 338.0K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 28.12 | N/A |
| Revenue | ★ $1,032,475,000.00 | N/A |
| Revenue This Year | $27.28 | $182.31 |
| Revenue Next Year | $16.97 | $65.19 |
| P/E Ratio | $34.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $870.01 | $90.39 |
| 52 Week High | $1,998.01 | $212.75 |
| Indicator | FICO | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 47.19 |
| Support Level | $888.00 | $119.68 |
| Resistance Level | $1,117.39 | $130.83 |
| Average True Range (ATR) | 40.51 | 5.04 |
| MACD | -5.76 | -0.94 |
| Stochastic Oscillator | 24.49 | 24.85 |
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.